Antifouling Efficacy on

Eskil André Karlsen, Mattias Berglin, Adam Hansson, Anders Oskar Lundgren, John S M Svendsen

Abstract read

In one paragraph

Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic.Journal of medicinal chemistry · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eskil André KarlsenAmicoat AS, Sykehusvegen 23, Tromsø 9019, Norway.

Mattias BerglinRISE Research Institutes of Sweden, Brinellgatan 4, Boras 504 62, Sweden.ORCID 0000-0002-9377-8924

Adam HanssonRISE Research Institutes of Sweden, Brinellgatan 4, Boras 504 62, Sweden.

Anders Oskar LundgrenDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg 40530, Sweden.ORCID 0000-0002-8537-9974

John S M SvendsenAmicoat AS, Sykehusvegen 23, Tromsø 9019, Norway.ORCID 0000-0001-5945-6123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cationic antimicrobial peptides (cAMPs) kill bacteria in solution by membrane lysis; however, translating cAMPs into a covalently attached antibacterial coating is challenging since it remains unclear how the specifics of the conjugation impact the antifouling efficacy. Furthermore, studies have typically assessed cAMP coatings with a high and homogeneous surface coverage, although this may be difficult to implement in practice of the materials commonly used in medicine. Herein, we investigate the antifouling efficacy of fractional surface coatings made from poly(ethylene glycol) (PEG)-tethered cAMPs presented on gold nanoparticles (AuNPs) deposited onto surfaces. For all tested cAMPs, the antifouling efficacy increases exponentially with the 2D surface coverage of the coating. However, although the cAMPs have a similar primary sequence and display similar potency against

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBiocompatible MaterialsBiofoulingGoldMetal NanoparticlesPolyethylene GlycolsStaphylococcus epidermidisMaterials TestingMicrobial Sensitivity TestsParticle SizeSurface PropertiesAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBiocompatible MaterialsGoldPolyethylene Glycolsantifoulingantimicrobial peptideCertikacontact anglegold nanoparticleToF-SIMS

Identifiers

PMID40373222

DOI10.1021/acsabm.5c00253

PMCPMC12175129

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.